메뉴 건너뛰기




Volumn 94, Issue 6, 2005, Pages 1138-1147

An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice

Author keywords

Clearance; Factor IX; Postranslational modifications; Recombinant proteins; Recovery

Indexed keywords

ANTITHROMBIN; COLLAGEN TYPE 4; RECOMBINANT BLOOD CLOTTING FACTOR 9; SERINE PROTEINASE;

EID: 29244464300     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-03-0201     Document Type: Article
Times cited : (26)

References (39)
  • 1
    • 0035822038 scopus 로고    scopus 로고
    • The hemophilias--from royal genes to gene therapy
    • Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9,
    • (2001) N Engl J Med , vol.344 , pp. 1773-1779
    • Mannucci, P.M.1    Tuddenham, E.G.2
  • 2
    • 0020500234 scopus 로고
    • Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor. Explanation for different electrophoretic radioactivity profiles obtained on activation of 3H-and 125I-labeled factor IX
    • Bajaj SP, Rapaport SI, Russell WA. Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor. Explanation for different electrophoretic radioactivity profiles obtained on activation of 3H-and 125I-labeled factor IX. Biochemistry 1983; 22: 4047-53.
    • (1983) Biochemistry , vol.22 , pp. 4047-4053
    • Bajaj, S.P.1    Rapaport, S.I.2    Russell, W.A.3
  • 3
    • 0019831499 scopus 로고
    • The role of phospholipid and factor VIIIa in the activation of bovine factor X
    • van Dieijen G, Tans G, Rosing J et al. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42.
    • (1981) J Biol Chem , vol.256 , pp. 3433-3442
    • van Dieijen, G.1    Tans, G.2    Rosing, J.3
  • 4
    • 0016703241 scopus 로고
    • Inhibition of human factor IXa by human antithrombin
    • Rosenberg JS, McKenna PW, Rosenberg RD. Inhibition of human factor IXa by human antithrombin. J Biol Chem 1975; 250: 8883-8.
    • (1975) J Biol Chem , vol.250 , pp. 8883-8888
    • Rosenberg, J.S.1    McKenna, P.W.2    Rosenberg, R.D.3
  • 5
    • 0034670013 scopus 로고    scopus 로고
    • Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein
    • Neels J, van den Berg B, Mertens K et al. Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. Blood 2000; 96: 3459-s65.
    • (2000) Blood , vol.96
    • Neels, J.1    van den Berg, B.2    Mertens, K.3
  • 6
    • 0029887334 scopus 로고    scopus 로고
    • The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP
    • Berntorp E. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. Baillieres Clin Haematol 1996; 9: 259-71.
    • (1996) Baillieres Clin Haematol , vol.9 , pp. 259-271
    • Berntorp, E.1
  • 7
    • 0030841284 scopus 로고    scopus 로고
    • High cost, low volume care: The ease of haemophilia
    • Lee C, Sabin C, Miners A. High cost, low volume care: the ease of haemophilia. BMJ 1997; 315: 962-3.
    • (1997) BMJ , vol.315 , pp. 962-963
    • Lee, C.1    Sabin, C.2    Miners, A.3
  • 8
    • 0036210038 scopus 로고    scopus 로고
    • Clinical outcomes and resource utilization associated with haemophilia care in Europe
    • Schramm W, Royal S, Kroner B et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
    • (2002) Haemophilia , vol.8 , pp. 33-43
    • Schramm, W.1    Royal, S.2    Kroner, B.3
  • 9
    • 0027411861 scopus 로고
    • Factor IX concentrates for clinical use
    • Thompson AR. Factor IX concentrates for clinical use. Semin Thromb Hemost 1993; 19: 25-36.
    • (1993) Semin Thromb Hemost , vol.19 , pp. 25-36
    • Thompson, A.R.1
  • 10
    • 0036484156 scopus 로고    scopus 로고
    • Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B
    • Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
    • (2002) Transfusion , vol.42 , pp. 190-197
    • Ewenstein, B.M.1    Joist, J.H.2    Shapiro, A.D.3
  • 11
    • 0036660414 scopus 로고    scopus 로고
    • Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
    • Gui T, Lin HF, Jin DY et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100: 153-8.
    • (2002) Blood , vol.100 , pp. 153-158
    • Gui, T.1    Lin, H.F.2    Jin, D.Y.3
  • 12
    • 0026660188 scopus 로고
    • The binding of human factor IX to endothelial cells is mediated by residues 3-11
    • Cheung WF, Hamaguchi N, Smith KJ et al. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem 1992; 267: 20529-31.
    • (1992) J Biol Chem , vol.267 , pp. 20529-20531
    • Cheung, W.F.1    Hamaguchi, N.2    Smith, K.J.3
  • 13
    • 15244354145 scopus 로고    scopus 로고
    • Factor IX variants improve gene therapy efficacy for hemophilia B
    • Schuettrumpf J, Herzog RW, Schlachterman A et al. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 2005; 105: 2316-23.
    • (2005) Blood , vol.105 , pp. 2316-2323
    • Schuettrumpf, J.1    Herzog, R.W.2    Schlachterman, A.3
  • 14
    • 0027532543 scopus 로고
    • Domain structure and domain-domain interactions in human coagulation factor IX
    • Vysotchin A, Medved LV, Ingham KC. Domain structure and domain-domain interactions in human coagulation factor IX. J Biol Chem 1993; 268: 8436-46.
    • (1993) J Biol Chem , vol.268 , pp. 8436-8446
    • Vysotchin, A.1    Medved, L.V.2    Ingham, K.C.3
  • 15
    • 17644445635 scopus 로고    scopus 로고
    • Biochemical characterization of recombinant factor IX
    • Bond M, Jankowski M, Patel H et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35: 11-7.
    • (1998) Semin Hematol , vol.35 , pp. 11-17
    • Bond, M.1    Jankowski, M.2    Patel, H.3
  • 17
    • 0033587143 scopus 로고    scopus 로고
    • Persistent delivery of factor IX in mice: Gene therapy for hemophilia using implantable microcapsules
    • Hortelano G, Xu N, Vandenberg A et al. Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules. Hum Gene Ther 1999; 10: 1281-8.
    • (1999) Hum Gene Ther , vol.10 , pp. 1281-1288
    • Hortelano, G.1    Xu, N.2    Vandenberg, A.3
  • 18
    • 0029685880 scopus 로고    scopus 로고
    • Immunoaffinity chromatography
    • Jack GW, Beer DJ. Immunoaffinity chromatography. Methods Mol Biol 1996; 59: 187-96.
    • (1996) Methods Mol Biol , vol.59 , pp. 187-196
    • Jack, G.W.1    Beer, D.J.2
  • 19
    • 4143091398 scopus 로고    scopus 로고
    • Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits
    • Sheffield WP, Mamdani A, Hortelano G et al. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004; 126: 565-73.
    • (2004) Br J Haematol , vol.126 , pp. 565-573
    • Sheffield, W.P.1    Mamdani, A.2    Hortelano, G.3
  • 20
    • 0016231936 scopus 로고
    • Comparative evaluation of a partial thromboplastin reagent containing a non-settling, particulate activator
    • Babson AL, Babson SR. Comparative evaluation of a partial thromboplastin reagent containing a non-settling, particulate activator. Am J Clin Pathol 1974; 62: 856-60.
    • (1974) Am J Clin Pathol , vol.62 , pp. 856-860
    • Babson, A.L.1    Babson, S.R.2
  • 21
    • 0030758328 scopus 로고    scopus 로고
    • A factor IX-deficient mouse model for hemophilia B gene therapy
    • Wang L, Zoppe M, Hackeng TM et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A 1997; 94: 11563-6.
    • (1997) Proc Natl Acad Sci U S A , vol.94 , pp. 11563-11566
    • Wang, L.1    Zoppe, M.2    Hackeng, T.M.3
  • 22
    • 0035082874 scopus 로고    scopus 로고
    • Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: Concurrent tumourigenesis
    • Hortelano G, Wang L, Xu N et al. Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis. Haemophilia 2001; 7: 207-14.
    • (2001) Haemophilia , vol.7 , pp. 207-214
    • Hortelano, G.1    Wang, L.2    Xu, N.3
  • 23
    • 0034663089 scopus 로고    scopus 로고
    • Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin
    • Ni H, Blajchman MA, Ananthanarayanan VS et al. Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. Thromb Res 2000; 99: 407-15.
    • (2000) Thromb Res , vol.99 , pp. 407-415
    • Ni, H.1    Blajchman, M.A.2    Ananthanarayanan, V.S.3
  • 24
    • 1242294497 scopus 로고    scopus 로고
    • A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin
    • McCurdy TR, Gataiance S, Eltringham-Smith LJ et al. A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin. J Lab Clin. Med 2004; 143: 115-24.
    • (2004) J Lab Clin. Med , vol.143 , pp. 115-124
    • McCurdy, T.R.1    Gataiance, S.2    Eltringham-Smith, L.J.3
  • 25
    • 0028877754 scopus 로고
    • An evaluation of numerical integration algorithms for the estimation of the area under the curve (AUC) in pharmacokinetic studies
    • Yu Z, Tse FL. An evaluation of numerical integration algorithms for the estimation of the area under the curve (AUC) in pharmacokinetic studies. Biopharm Drug Dispos 1995; 16: 37-58.
    • (1995) Biopharm Drug Dispos , vol.16 , pp. 37-58
    • Yu, Z.1    Tse, F.L.2
  • 26
    • 0024594530 scopus 로고
    • Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation
    • Van Ryn-McKenna J, Ofosu FA, Hirsh J et al. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation. Br J Haematol 1989; 71: 265-9.
    • (1989) Br J Haematol , vol.71 , pp. 265-269
    • Van Ryn-McKenna, J.1    Ofosu, F.A.2    Hirsh, J.3
  • 27
    • 0030899507 scopus 로고    scopus 로고
    • Factor IX activation by factor XIa proceeds without release of a free intermediate
    • Wolberg AS, Morris DP, Stafford DW. Factor IX activation by factor XIa proceeds without release of a free intermediate. Biochemistry 1997; 36: 4074-9.
    • (1997) Biochemistry , vol.36 , pp. 4074-4079
    • Wolberg, A.S.1    Morris, D.P.2    Stafford, D.W.3
  • 28
    • 17644445635 scopus 로고    scopus 로고
    • Biochemical characterization of recombinant factor IX
    • Bond M, Jankowski M, Patel H et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35: 11-17.
    • (1998) Semin Hematol , vol.35 , pp. 11-17
    • Bond, M.1    Jankowski, M.2    Patel, H.3
  • 29
    • 0024321508 scopus 로고
    • Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of beta-galactoside alpha 2,6-sialyltransferase
    • Lee EU, Roth J, Paulson JC. Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of beta-galactoside alpha 2,6-sialyltransferase. J Biol Chem 1989; 264: 13848-55.
    • (1989) J Biol Chem , vol.264 , pp. 13848-13855
    • Lee, E.U.1    Roth, J.2    Paulson, J.C.3
  • 30
    • 0024278423 scopus 로고
    • The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues
    • Wang WC, Cummings RD. The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues. J Biol Chem 1988; 263: 4576-85.
    • (1988) J Biol Chem , vol.263 , pp. 4576-4585
    • Wang, W.C.1    Cummings, R.D.2
  • 31
    • 0023644482 scopus 로고
    • The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence
    • Shibuya N, Goldstein IJ, Broekaert WF et al. The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence. J Biol Chem 1987; 262: 1596-601.
    • (1987) J Biol Chem , vol.262 , pp. 1596-1601
    • Shibuya, N.1    Goldstein, I.J.2    Broekaert, W.F.3
  • 32
    • 29244489676 scopus 로고    scopus 로고
    • Role of the activation peptide in factor IX activation
    • Chang J-Y, Allen GA, Monroe DM et al. Role of the activation peptide in factor IX activation. Blood 2000; 96: 632a.
    • (2000) Blood , vol.96
    • Chang, J.-Y.1    Allen, G.A.2    Monroe, D.M.3
  • 33
    • 0028873221 scopus 로고
    • Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog
    • Keith JC, Jr., Ferranti TJ, Misra B et al. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost 1995; 73: 101-5.
    • (1995) Thromb Haemost , vol.73 , pp. 101-105
    • Keith Jr., J.C.1    Ferranti, T.J.2    Misra, B.3
  • 34
    • 0021287957 scopus 로고
    • Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors
    • Fuchs HE, Trapp HG, Griffith MJ et al. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J Clin Invest 1984; 73: 1696-703.
    • (1984) J Clin Invest , vol.73 , pp. 1696-1703
    • Fuchs, H.E.1    Trapp, H.G.2    Griffith, M.J.3
  • 35
    • 0034846845 scopus 로고    scopus 로고
    • A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro
    • Marques JA, George JK, Smith IJ et al. A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. Thromb Haemost 2001; 86: 902-8.
    • (2001) Thromb Haemost , vol.86 , pp. 902-908
    • Marques, J.A.1    George, J.K.2    Smith, I.J.3
  • 36
    • 0030942608 scopus 로고    scopus 로고
    • Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin
    • Syed S, Schuyler PD, Kulczycky M et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 1997; 89: 3243-52.
    • (1997) Blood , vol.89 , pp. 3243-3252
    • Syed, S.1    Schuyler, P.D.2    Kulczycky, M.3
  • 38
    • 0036660414 scopus 로고    scopus 로고
    • Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
    • Gui T, Lin HF, Jin DY et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100: 153-8.
    • (2002) Blood , vol.100 , pp. 153-158
    • Gui, T.1    Lin, H.F.2    Jin, D.Y.3
  • 39
    • 0032524615 scopus 로고    scopus 로고
    • Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity
    • Chang J, Jin J, Lollar P et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem 1998; 273: 12089-94.
    • (1998) J Biol Chem , vol.273 , pp. 12089-12094
    • Chang, J.1    Jin, J.2    Lollar, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.